Full-Time

Senior Manager

Content Engine

Posted on 9/15/2025

Deadline 9/30/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$120.8k - $201.4k/yr

+ Bonus

No H1B Sponsorship

New York, NY, USA

Hybrid

Hybrid, 2-3x a week onsite.

Category
Growth & Marketing (2)
,
Required Skills
SEO
Data Analysis
Requirements
  • Applicant must have a bachelor's degree with at least 6 years of experience; OR a master's degree with at least 5 years of experience; OR a PhD with 1+ years of experience.
  • 6+ years of experience either in-house or at the agency setting
  • Successful track record designing and implementing high-impact content campaigns from conception through execution
  • Project management skills coordinating multifaceted campaigns and initiatives
  • Forward-thinking mindset with the creativity and vision to build innovative solutions for unmet needs
  • Strong written communication skills
  • Mastery in staying compliant with the complex legal and regulatory guidelines surrounding branded content
  • Skilled at communicating compelling narratives and campaign visions
  • Adept at persuading both internal and external stakeholders of the merits and potential business value of proposed ideas and strategies
  • Strong relationship building skills and ability to navigate matrixed organizations
  • Drives strategy while simultaneously orchestrating flawless execution at speed
  • Embodies courage, excellence, equity, and joy while elevating those values across teams
  • Executive poise and influence to interact effectively across all organizational levels
  • Articulate communicator able to optimize messaging and design for maximum user resonance and business impact
  • Exercises discretion and maintains trustworthiness when dealing with sensitive confidential information.
Responsibilities
  • Support the Director, Content Engine Lead in building a first of its kind Center of Excellence dedicated to content that drives SEO, GEO, and social search.
  • Create and lead the development of a company-wide content engine playbook that connects insights with content actions and how best to measure impact.
  • Work hand in hand with brand marketers and cross-functional teams to guide on content strategies that align with our brand teams’ objectives and resonates with our target audience; establish plans to test and learn.
  • Oversee the creation of high-quality content created by either an in-house team or external partners that enriches storytelling and drives engagement across various organic, search-driven platforms. Ensure all content is on-brand, compelling, consistent in style, quality, and tone of voice.
  • Build a process for, and then own the end-to-end production of content where our AOR isn’t resourced to support our brands with agile, quick turn opportunistic content; support in creating the model of quick-turn content creation.
  • Drive engagement and conversion through innovative content distribution tactics across multiple channels.
  • Lead cross-function work to collaborate with CMO colleagues including SEO, Product (website), Measurement, Social Listening, and Media Strategists, to ensure cohesive messaging and branding consistency, and that content supports overall marketing / media and business goals.
  • Where needed, develop and maintain a content calendar to ensure timely delivery of content and campaigns on above-brand sites like PfizerForAll.com.
  • Collaborate with technical teams and SEO/GEO specialists to ensure best practices are embedded in content creation and distribution processes.
  • Utilize analytics tools to measure content effectiveness, derive insights, and adjust strategies to optimize engagement and conversion rates.
  • Manage the content budget, ensuring efficient allocation of resources and ROI.
  • Stay informed of industry trends, competitor strategies, and emerging technologies to keep our content strategies culturally relevant and ahead of the curve.
Desired Qualifications
  • Passionate About Storytelling: You believe in the power of content to tell stories that resonate and inspire action.
  • Innovative Thinker: You constantly identify insights that inform and shape effective content strategies.
  • Inquisitive Nature: You ask thoughtful questions, listen deeply, and seek meaningful answers.
  • Strategic and Tactical: You excel at conceptualizing big-picture ideas and effectively managing projects from inception to completion.
  • Norm Challenger: You question "the way things are done," explore innovative new approaches, and embrace learning from failure.
  • People Person: You thrive on engaging with audiences and cultivating strong relationships.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE